ArticleInternational journal of molecular sciences2025
Multiplexed Quantitation of Plasma Proteins by Targeted Mass Spectrometry for Early Diagnosis of Pancreatic Ductal Adenocarcinoma.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pancreatic cancer (PC) is the sixth leading cause of cancer-related deaths worldwide. Patients with pancreatic ductal adenocarcinoma (PDAC), the most common type of PC, have a 5-year survival rate of approximately 10%. This low survival rate is mainly attributed to late-stage diagnoses and the lack of robust screening methods. Several serum proteins have been proposed as potential PDAC biomarkers, but they have not been introduced into clinical practice due to their low sensitivity and specificity. Therefore, the identification of new PDAC biomarkers remains highly important, and multiple reaction monitoring (MRM), a highly accurate mass spectrometry (MS) technique, can be used for this purpose. Using MRM MS analysis, we estimated the concentrations of 103 proteins in peripheral blood plasma from 132 participants: patients with newly diagnosed PDAC at different stages and healthy individuals. We identified six proteins that were differentially presented between healthy controls and patients with PDAC at all stages (adjusted
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.